Idelalisib-Rituximab induces clinical remissions in patients with TP53 disrupted B cell prolymphocytic leukaemia-Reference-Cited by-同舟云学术

Idelalisib-Rituximab induces clinical remissions in patients with TP53 disrupted B cell prolymphocytic leukaemia

Published:2016-04-07 Issue:3 Volume:177 Page:486-491
ISSN:0007-1048
Container-title:British Journal of Haematology
language:en
Short-container-title:Br J Haematol

Author:

Eyre Toby A.¹,Fox Christopher P.²,Shankara Paneesha³,Went Richard⁴,Schuh Anna H.¹⁵⁶

Affiliation:

1. Department of Haematology; Oxford University Hospitals NHS Trust; Churchill Hospital; Oxford UK

2. Department of Clinical Haematology; Nottingham University Hospitals NHS Trust, City Campus; Nottingham UK

3. Department of Haematology & Stem Cell Transplantation; Birmingham Heartlands Hospital; Birmingham UK

4. Department of Clinical Haematology; The Rotherham NHS Foundation Trust; Rotherham South Yorkshire UK

5. NIHR BRC Oxford Molecular Diagnostic Centre; Oxford University Hospitals NHS Trust and Department of Oncology; University of Oxford; John Radcliffe Hospital; Oxford UK

6. Department of Oncology; University of Oxford; Oxford UK

Funder

Julian Starmer-Smith Lymphoma Fund

NIHR Biomedical Research Centre (Oxford)

Publisher

Wiley

Subject

Hematology

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1111/bjh.14066/fullpdf

Reference10 articles.

1. Survival of leukemic B cells promoted by engagement of the antigen receptor;Bernal;Blood,2001

2. Allogeneic peripheral stem-cell transplantation with reduced-intensity conditioning regimen in refractory primary B-cell prolymphocytic leukemia: a long-term follow-up;Castagna;Bone Marrow Transplantation,2005

3. Complete response to alemtuzumab in a patient with B prolymphocytic leukemia;Chaar;American Journal of Hematology,2007

4. How I treat prolymphocytic leukemia;Dearden;Blood,2012

5. Pentostatin in prolymphocytic leukemia: phase II trial of the European Organization for Research and Treatment of Cancer Leukemia Cooperative Study Group;Döhner;Journal of the National Cancer Institute,1993

Cited by 12 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Retrospective analysis of a cohort of 41 <i>de novo</i> B-cell prolymphocytic leukemia patients: impact of genetics and targeted therapies (a FILO study);Haematologica;2022-12-22

2. A new case of trisomy 5 with complex karyotype abnormalities in B-cell prolymphocytic leukemia: a case study;Egyptian Journal of Medical Human Genetics;2022-03-03

3. A retrospective observational study to evaluate the clinical outcomes and routine management of patients with chronic lymphocytic leukaemia treated with idelalisib and rituximab in the UK and Ireland (RETRO‐idel);British Journal of Haematology;2021-06-14

4. Effective upfront treatment with low-dose ibrutinib for a patient with B cell prolymphocytic leukemia;Investigational New Drugs;2020-01-22

5. B-cell prolymphocytic leukemia successfully treated with B-cell receptor antagonists, but resistant to venetoclax;Leukemia & Lymphoma;2019-11-12